51
|
Acharya S, Adamová D, Adler A, Adolfsson J, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Akbar Z, Akindinov A, Al-Turany M, Albuquerque DSD, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Anaam MN, Andrei C, Andreou D, Andronic A, Anguelov V, Antičić T, Antinori F, Antonioli P, Anuj C, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arratia M, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bai X, Bailhache R, Bala R, Balbino A, Baldisseri A, Ball M, Banerjee D, Barbera R, Barioglio L, Barlou M, Barnaföldi GG, Barnby LS, Barret V, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Berenyi D, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhat IR, Bhat MA, Bhattacharjee B, Bhattacharya P, Bianchi A, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Bilandzic A, Biro G, Biswas S, Blair JT, Blau D, Blidaru MB, Blume C, Boca G, Bock F, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond PM, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buncic P, Buthelezi Z, Butt JB, Bysiak SA, Caffarri D, Caliva A, Calvo Villar E, Camacho JMM, Camacho RS, Camerini P, Canedo FDM, Capon AA, Carnesecchi F, Caron R, Castillo Castellanos J, Casula EAR, Catalano F, Ceballos Sanchez C, Chakraborty P, Chandra S, Chang W, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Chavez TG, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Ciupek MR, Clai G, Cleymans J, Colamaria F, Colburn JS, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Cormier TM, Cortese P, Cosentino MR, Costa F, Costanza S, Crochet P, Cuautle E, Cui P, Cunqueiro L, Dainese A, Damas FPA, Danisch MC, Danu A, Das I, Das P, Das P, Das S, Dash S, De S, De Caro A, de Cataldo G, De Cilladi L, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Degenhardt HF, Deja KR, Dello Stritto L, Delsanto S, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Do J, Dobrin A, Dönigus B, Dordic O, Dubey AK, Dubla A, Dudi S, Dukhishyam M, Dupieux P, Eder TM, Ehlers RJ, Eikeland VN, Elia D, Erazmus B, Ercolessi F, Erhardt F, Erokhin A, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Festanti A, Feuillard VJG, Figiel J, Filchagin S, Finogeev D, Fionda FM, Fiorenza G, Flor F, Flores AN, Foertsch S, Foka P, Fokin S, Fragiacomo E, Fuchs U, Funicello N, Furget C, Furs A, Fusco Girard M, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gauger EF, Gay Ducati MB, Germain M, Ghosh J, Ghosh P, Ghosh SK, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Gonzalez V, González-Trueba LH, Gorbunov S, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Graham KL, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Groettvik OS, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guernane R, Guilbaud M, Guittiere M, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Guzman IB, Haake R, Habib MK, Hadjidakis C, Hamagaki H, Hamar G, Hamid M, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hasenbichler JA, Hassan H, Hatzifotiadou D, Hauer P, Havener LB, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herman T, Hernandez EG, Herrera Corral G, Herrmann F, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hohlweger B, Honermann J, Hong GH, Horak D, Hornung S, Hosokawa R, Hristov P, Huang C, Hughes C, Huhn P, Humanic TJ, Hushnud H, Husova LA, Hussain N, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Janson T, Jercic M, Jevons O, Jin M, Jonas F, Jones PG, Jung J, Jung M, Junique A, Jusko A, Kalinak P, Kalweit A, Kaplin V, Kar S, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Keil M, Ketzer B, Khabanova Z, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim D, Kim DJ, Kim EJ, Kim H, Kim J, Kim JS, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe AG, Kobdaj C, Köhler MK, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koryciak SD, Koska L, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Kryshen E, Krzewicki M, Kučera V, Kuhn C, Kuijer PG, Kumaoka T, Kumar L, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lakrathok A, Lamanna M, Langoy R, Lapidus K, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Lee J, Lehrbach J, Lemmon RC, León Monzón I, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lim SH, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu J, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmood SM, Mahmoud T, Maire A, Majka RD, Malaev M, Malik QW, Malinina L, Mal'Kevich D, Mallick N, Malzacher P, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Mareš J, Margagliotti GV, Margotti A, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazuecos AL, Mazzaschi F, Mazzilli M, Mazzoni MA, Mechler AF, Meddi F, Melikyan Y, Menchaca-Rocha A, Mengke C, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohammadi N, Mohanty AP, Mohanty B, Khan MM, Moravcova Z, Mordasini C, Moreira De Godoy DA, Moreno LAP, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myers CJ, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Naru MU, Nassirpour AF, Nattrass C, Nazarenko S, Neagu A, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Osako T, Oskarsson A, Otwinowski J, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Pan J, Panebianco S, Pareek P, Park J, Parkkila JE, Parmar S, Pathak SP, Paul B, Pazzini J, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Poljak N, Pop A, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Ramos AGT, Raniwala R, Raniwala S, Räsänen SS, Rath R, Ravasenga I, Read KF, Redelbach AR, Redlich K, Rehman A, Reichelt P, Reidt F, Renfordt R, Rescakova Z, Reygers K, Riabov A, Riabov V, Richert T, Richter M, Riedler P, Riegler W, Riggi F, Ristea C, Rode SP, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski TS, Rohr D, Röhrich D, Rojas PF, Rokita PS, Ronchetti F, Rosano A, Rosas ED, Rossi A, Rotondi A, Roy A, Roy P, Rubini N, Rueda OV, Rui R, Rumyantsev B, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki OAM, Sadek R, Sadovsky S, Saetre J, Šafařík K, Saha SK, Saha S, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu D, Sahu PK, Saini J, Sakai S, Sambyal S, Samsonov V, Sarkar D, Sarkar N, Sarma P, Sarti VM, Sas MHP, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schotter R, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo JJ, Serebryakov D, Šerkšnytė L, Sevcenco A, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma H, Sharma M, Sharma N, Sharma S, Sheibani O, Sheikh AI, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva TFD, Silvermyr D, Simatovic G, Simonetti G, Singh B, Singh R, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Skorodumovs G, Slupecki M, Smirnov N, Snellings RJM, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Steffanic PJ, Stiefelmaier SF, Stocco D, Storetvedt MM, Stylianidis CP, Suaide AAP, Sugitate T, Suire C, Suljic M, Sultanov R, Šumbera M, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tang Z, Tarhini M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tieulent R, Tikhonov A, Timmins AR, Tkacik M, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Torres SR, Trifiró A, Tripathy S, Tripathy T, Trogolo S, Trombetta G, Trubnikov V, Trzaska WH, Trzcinski TP, Trzeciak BA, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Umaka EN, Uras A, Urioni M, Usai GL, Vala M, Valle N, Vallero S, van der Kolk N, van Doremalen LVR, van Leeuwen M, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vargas A, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vrláková J, Wagner B, Weber M, Wegrzynek A, Wenzel SC, Wessels JP, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Willsher E, Windelband B, Winn M, Witt WE, Wright JR, Wu Y, Xu R, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yuan S, Yuncu A, Yurchenko V, Zaccolo V, Zaman A, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zhalov M, Zhang S, Zhang X, Zhang Y, Zherebchevskii V, Zhi Y, Zhou D, Zhou Y, Zhu J, Zhu Y, Zichichi A, Zinovjev G, Zurlo N. Multiharmonic Correlations of Different Flow Amplitudes in Pb-Pb Collisions at sqrt[s_{NN}]=2.76 TeV. PHYSICAL REVIEW LETTERS 2021; 127:092302. [PMID: 34506195 DOI: 10.1103/physrevlett.127.092302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2021] [Revised: 06/09/2021] [Accepted: 07/13/2021] [Indexed: 06/13/2023]
Abstract
The event-by-event correlations between three flow amplitudes are measured for the first time in Pb-Pb collisions, using higher-order symmetric cumulants. We find that different three-harmonic correlations develop during the collective evolution of the medium when compared to correlations that exist in the initial state. These new results cannot be interpreted in terms of previous lower-order flow measurements since contributions from two-harmonic correlations are explicitly removed in the new observables. A comparison to Monte Carlo simulations provides new and independent constraints for the initial conditions and system properties of nuclear matter created in heavy-ion collisions.
Collapse
|
52
|
Tang S, Jones C, Coward K. P-798 Fertility preservation in pre-pubertal boys with cancer: A three-dimensional prepubertal testicular organoid for in vitro spermatogonial stem cell propagation and spermatogenesis. Hum Reprod 2021. [DOI: 10.1093/humrep/deab128.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Can a three-dimensional (3D) prepubertal testicular organoid be formed and provide an in vitro microenvironment for spermatogonial stem cells (SSCs) maintenance and future spermatogenesis?
Summary answer
Primary cells extracted from immature testicular tissue (ITT) or SSCs can be grown long-term as 3D organoids, providing the potential for in vitro study.
What is known already
Aggressive cancer treatments, such as chemo- or radiotherapy, can leave young prepubertal boys infertile. Such patients are recommended to undergo the cryopreservation of testicular material to protect future fertility. Within the testes, the specialized 3D structure and direct cell-to-cell interactions play a critical role in the proliferation and development of SSCs. Over recent decades, 3D culture systems and organoids have been used to culture cells in vitro, however, a system that allows investigations into testicular organogenesis in vitro, and its impact on the SSC niche, has yet to be developed.
Study design, size, duration
This study aims to develop a 3D organoid culture system to support the proliferation of SSCs and spermatogenesis. Primary bovine ITT cells and enriched SSCs were isolated and 3D organoids were generated by in vitro culture for up to 40 days. Organoid formation was observed after using different foundation cells seeded at different densities and cultured in medium containing gonadotropic supplements.
Participants/materials, setting, methods
Post-thaw bovine ITTs (2 weeks-of-age) were dissociated using two-step enzymatic digestion. Enriched SSCs were selected by Percoll gradients and differential plating. Viability and apoptosis were evaluated by trypan blue staining and TUNEL assays, respectively. SSCs were evaluated immunocytochemically for germ-cell markers (PGP-9.5, PLZF) and Sertoli cell markers (Vimentin, Sox9). Expression levels of SSCs and spermatogenesis-related genes (Plzf, Gfrα-1, Nanog, Oct4, Stra8, Thy1) were determined by real-time quantitative polymerase chain reaction (RT-qPCR).
Main results and the role of chance
The viability of digested cells from thawed ITTs was 78.667% ± 2.03. Total testicular cells (<10% SSCs) and enriched SSCs(>50% SSCs) were observed to self-assemble into structurally complex organoids recapitulating the cell type compartmentalization of the testis, in a 3D Matrigel-based culture system with 10% knockout serum replacement (KSR) culture medium, but not with 10% fetal bovine serum(FBS) medium. Testicular organoids were found to exhibit either a grape-like structure and a round-shape structure. Cytoplasmic extensions of spermatogonia/Sertoli cells were in contact with each other within a forming colony. Organoids were formed faster and larger when seeded at a final concentration of 1.5 × 106 cells/ml, compared to 5 × 105 cells/ml and 1.5 × 105 cells/ml. Organoids grew to a diameter of 400 μm within 10 - 15 days and were passaged by mechanical disruption at a ratio of 1:3 every 7 - 10 days. Immunocytochemistry results showed that clusters of PGP9.5 and PLZF-positive cells were present within the organoids. The expression of selected germ cell and spermatogenesis markers in the testicular organoids closely resembled that of primary testicular cells for up to 20 days of culture.
Limitations, reasons for caution
We used calves (2 weeks-of-age) as an animal model to study testicular organoids. This tissue may act differently than human tissues and may not fully represent prepuberty. Furthermore, we only evaluated gene expression levels for selected markers that may not represent the full functional capability of germ cells.
Wider implications of the findings
Testicular organoids, as an in vitro bioengineering testicular model, could potentially be used to study testicular tissue development, cellular interactions, endocrinology, and spermatogenesis, in the laboratory but may also be applied for clinical purposes in the future.
Trial registration number
University of Oxford
Collapse
|
53
|
Tang S, Jones C, Coward K. P–798 Fertility preservation in pre-pubertal boys with cancer: A three-dimensional prepubertal testicular organoid for in vitro spermatogonial stem cell propagation and spermatogenesis. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Can a three-dimensional (3D) prepubertal testicular organoid be formed and provide an in vitro microenvironment for spermatogonial stem cells (SSCs) maintenance and future spermatogenesis?
Summary answer
Primary cells extracted from immature testicular tissue (ITT) or SSCs can be grown long-term as 3D organoids, providing the potential for in vitro study.
What is known already
Aggressive cancer treatments, such as chemo- or radiotherapy, can leave young prepubertal boys infertile. Such patients are recommended to undergo the cryopreservation of testicular material to protect future fertility. Within the testes, the specialized 3D structure and direct cell-to-cell interactions play a critical role in the proliferation and development of SSCs. Over recent decades, 3D culture systems and organoids have been used to culture cells in vitro, however, a system that allows investigations into testicular organogenesis in vitro, and its impact on the SSC niche, has yet to be developed.
Study design, size, duration
This study aims to develop a 3D organoid culture system to support the proliferation of SSCs and spermatogenesis. Primary bovine ITT cells and enriched SSCs were isolated and 3D organoids were generated by in vitro culture for up to 40 days. Organoid formation was observed after using different foundation cells seeded at different densities and cultured in medium containing gonadotropic supplements.
Participants/materials, setting, methods
Post-thaw bovine ITTs (2 weeks-of-age) were dissociated using two-step enzymatic digestion. Enriched SSCs were selected by Percoll gradients and differential plating. Viability and apoptosis were evaluated by trypan blue staining and TUNEL assays, respectively. SSCs were evaluated immunocytochemically for germ-cell markers (PGP–9.5, PLZF) and Sertoli cell markers (Vimentin, Sox9). Expression levels of SSCs and spermatogenesis-related genes (Plzf, Gfrα–1, Nanog, Oct4, Stra8, Thy1) were determined by real-time quantitative polymerase chain reaction (RT-qPCR).
Main results and the role of chance
The viability of digested cells from thawed ITTs was 78.667% ± 2.03. Total testicular cells (<10% SSCs) and enriched SSCs(>50% SSCs) were observed to self-assemble into structurally complex organoids recapitulating the cell type compartmentalization of the testis, in a 3D Matrigel-based culture system with 10% knockout serum replacement (KSR) culture medium, but not with 10% fetal bovine serum(FBS) medium. Testicular organoids were found to exhibit either a grape-like structure and a round-shape structure. Cytoplasmic extensions of spermatogonia/Sertoli cells were in contact with each other within a forming colony. Organoids were formed faster and larger when seeded at a final concentration of 1.5 × 106 cells/ml, compared to 5 × 105 cells/ml and 1.5 × 105 cells/ml. Organoids grew to a diameter of 400 μm within 10 - 15 days and were passaged by mechanical disruption at a ratio of 1:3 every 7 - 10 days. Immunocytochemistry results showed that clusters of PGP9.5 and PLZF-positive cells were present within the organoids. The expression of selected germ cell and spermatogenesis markers in the testicular organoids closely resembled that of primary testicular cells for up to 20 days of culture.
Limitations, reasons for caution
We used calves (2 weeks-of-age) as an animal model to study testicular organoids. This tissue may act differently than human tissues and may not fully represent prepuberty. Furthermore, we only evaluated gene expression levels for selected markers that may not represent the full functional capability of germ cells.
Wider implications of the findings: Testicular organoids, as an in vitro bioengineering testicular model, could potentially be used to study testicular tissue development, cellular interactions, endocrinology, and spermatogenesis, in the laboratory but may also be applied for clinical purposes in the future.
Trial registration number
University of Oxford
Collapse
|
54
|
Zhu D, Qiao J, Tang S, Pan Y, Li S, Yang C, Fang H. Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis. Rheumatology (Oxford) 2021; 60:3896-3903. [PMID: 33398346 DOI: 10.1093/rheumatology/keaa819] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 11/16/2020] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES The present study aimed to determine the correlation between serum carcinoembryonic antigen (CEA) level and the severity of interstitial lung disease (ILD) in clinically amyopathic DM (CADM) patients. METHODS We performed a retrospective study including 41 Chinese CADM patients without malignancy. Serum CEA levels, clinical and laboratory findings were collected. Association tests between CEA levels and disease activity parameters were performed. RESULTS Among the 41 patients, 16 (39.0%) developed rapidly progressive (RP)-ILD; of them, 14 (87.5%) had elevated serum CEA levels. Multivariate logistic regression analysis indicated that an elevated serum CEA level was an independent risk factor for RP-ILD. The incidence of elevated CEA level was significantly higher in patients with RP-ILD than in those without RP-ILD (87.5 vs 16.0%, P < 0.001). Furthermore, CEA levels were higher in patients with CADM with RP-ILD [26.87 (6.71) μg/l] than in those without RP-ILD [3.23 (0.64) μg/l] (P < 0.001). CEA levels in CADM patients were associated with the ferritin, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase levels, and CT scores of the lungs. Also, elevated CEA levels are related to the organizing pneumonia pattern and lower lung zone consolidation in high-resolution CT. Moreover, the cumulative survival rate was significantly lower (68.4 vs 31.6%, P < 0.001) in the group with a CEA level >8.75 μg/l than that in the group with a CEA level <8.75 μg/l. CONCLUSIONS An elevated serum CEA level is common in patients with CADM, and a higher serum CEA level is a powerful indicator of RP-ILD and poor prognosis in those patients.
Collapse
|
55
|
Ding X, Zhao L, Liu G, Zheng W, Shen J, Lee A, Di Y, Deraniyagala R, Stevens C, Li X, Tang S. PD-0902 Do we need a precise proton machine-specific delivery sequence to assess the interplay effect? Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07181-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
56
|
Acharya S, Adamová D, Adler A, Adolfsson J, Aggarwal MM, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Akbar Z, Akindinov A, Al-Turany M, Alam SN, Albuquerque DSD, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Anaam MN, Andrei C, Andreou D, Andronic A, Angeletti M, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arratia M, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bagnasco S, Bai X, Bailhache R, Bala R, Balbino A, Baldisseri A, Ball M, Balouza S, Banerjee D, Barbera R, Barioglio L, Barnaföldi GG, Barnby LS, Barret V, Bartalini P, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Bedda C, Behera NK, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berenyi D, Bertens RA, Berzano D, Besoiu MG, Betev L, Bhasin A, Bhat IR, Bhat MA, Bhatt H, Bhattacharjee B, Bianchi A, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Bilandzic A, Biro G, Biswas R, Biswas S, Blair JT, Blau D, Blume C, Boca G, Bock F, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruna E, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buncic P, Buthelezi Z, Butt JB, Bysiak SA, Caffarri D, Caliva A, Calvo Villar E, Camacho JMM, Camacho RS, Camerini P, Canedo FDM, Capon AA, Carnesecchi F, Caron R, Castillo Castellanos J, Castro AJ, Casula EAR, Catalano F, Ceballos Sanchez C, Chakraborty P, Chandra S, Chang W, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Chowdhury T, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cilladi LD, Cindolo F, Ciupek MR, Clai G, Cleymans J, Colamaria F, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Cormier TM, Corrales Morales Y, Cortese P, Cosentino MR, Costa F, Costanza S, Crochet P, Cuautle E, Cui P, Cunqueiro L, Dabrowski D, Dahms T, Dainese A, Damas FPA, Danisch MC, Danu A, Das D, Das I, Das P, Das P, Das S, Dash A, Dash S, De S, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, Deb S, Degenhardt HF, Deja KR, Deloff A, Delsanto S, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Dillenseger P, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Dobrin A, Dönigus B, Dordic O, Dubey AK, Dubla A, Dudi S, Dukhishyam M, Dupieux P, Ehlers RJ, Eikeland VN, Elia D, Erazmus B, Erhardt F, Erokhin A, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Festanti A, Feuillard VJG, Figiel J, Filchagin S, Finogeev D, Fionda FM, Fiorenza G, Flor F, Flores AN, Foertsch S, Foka P, Fokin S, Fragiacomo E, Frankenfeld U, Fuchs U, Furget C, Furs A, Fusco Girard M, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gauger EF, Gay Ducati MB, Germain M, Ghosh J, Ghosh P, Ghosh SK, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Gomez Ramirez A, Gonzalez V, González-Trueba LH, Gorbunov S, Görlich L, Goswami A, Gotovac S, Grabski V, Graczykowski LK, Graham KL, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Groettvik OS, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guernane R, Guittiere M, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Guzman IB, Haake R, Habib MK, Hadjidakis C, Hamagaki H, Hamar G, Hamid M, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hasenbichler JA, Hassan H, Hassan QU, Hatzifotiadou D, Hauer P, Havener LB, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herghelegiu A, Herman T, Hernandez EG, Herrera Corral G, Herrmann F, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hohlweger B, Honermann J, Horak D, Hornung A, Hornung S, Hosokawa R, Hristov P, Huang C, Hughes C, Huhn P, Humanic TJ, Hushnud H, Husova LA, Hussain N, Hussain SA, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Janson T, Jercic M, Jevons O, Jin M, Jonas F, Jones PG, Jung J, Jung M, Jusko A, Kalinak P, Kalweit A, Kaplin V, Kar S, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Keil M, Ketzer B, Khabanova Z, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim B, Kim D, Kim DJ, Kim EJ, Kim H, Kim J, Kim JS, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein C, Klein J, Klein S, Klein-Bösing C, Kleiner M, Kluge A, Knichel ML, Knospe AG, Kobdaj C, Köhler MK, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koska L, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Krüger M, Kryshen E, Krzewicki M, Kubera AM, Kučera V, Kuhn C, Kuijer PG, Kumar L, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lamanna M, Langoy R, Lapidus K, Lardeux A, Larionov P, Laudi E, Lavicka R, Lazareva T, Lea R, Leardini L, Lee J, Lee S, Lehner S, Lehrbach J, Lemmon RC, León Monzón I, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lindenstruth V, Lindner A, Lippmann C, Lisa MA, Liu A, Liu J, Liu S, Llope WJ, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmood SM, Mahmoud T, Maire A, Majka RD, Malaev M, Malik QW, Malinina L, Mal'Kevich D, Malzacher P, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Marchisone M, Mareš J, Margagliotti GV, Margotti A, Marín A, Markert C, Marquard M, Martin CD, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Masson E, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazzaschi F, Mazzilli M, Mazzoni MA, Mechler AF, Meddi F, Melikyan Y, Menchaca-Rocha A, Mengke C, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohammadi N, Mohanty AP, Mohanty B, Mohisin Khan M, Moravcova Z, Mordasini C, Moreira De Godoy DA, Moreno LAP, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myers CJ, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Naru MU, Nassirpour AF, Nattrass C, Nayak R, Nayak TK, Nazarenko S, Neagu A, Negrao De Oliveira RA, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Neumann LT, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Oppedisano C, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oyama K, Pachmayer Y, Pacik V, Padhan S, Pagano D, Paić G, Pan J, Panebianco S, Pareek P, Park J, Parkkila JE, Parmar S, Pathak SP, Paul B, Pazzini J, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Pistone D, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Poljak N, Pop A, Porteboeuf-Houssais S, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Putschke J, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Raha S, Rajput S, Rak J, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Raniwala R, Raniwala S, Räsänen SS, Rath R, Ratza V, Ravasenga I, Read KF, Redelbach AR, Redlich K, Rehman A, Reichelt P, Reidt F, Ren X, Renfordt R, Rescakova Z, Reygers K, Riabov A, Riabov V, Richert T, Richter M, Riedler P, Riegler W, Riggi F, Ristea C, Rode SP, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rohr D, Röhrich D, Rojas PF, Rokita PS, Ronchetti F, Rosano A, Rosas ED, Roslon K, Rossi A, Rotondi A, Roy A, Roy P, Rueda OV, Rui R, Rumyantsev B, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Saarimaki OAM, Sadek R, Sadhu S, Sadovsky S, Šafařík K, Saha SK, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu PK, Saini J, Sakai S, Sambyal S, Samsonov V, Sarkar D, Sarkar N, Sarma P, Sarti VM, Sas MHP, Scapparone E, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Serebryakov D, Sevcenco A, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma A, Sharma H, Sharma M, Sharma N, Sharma S, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silvermyr D, Simatovic G, Simonetti G, Singh B, Singh R, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Slupecki M, Smirnov N, Snellings RJM, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Steffanic PJ, Stenlund E, Stiefelmaier SF, Stocco D, Storetvedt MM, Stritto LD, Suaide AAP, Sugitate T, Suire C, Suleymanov M, Suljic M, Sultanov R, Šumbera M, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tarhini M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Thakur D, Thakur S, Thomas D, Thoresen F, Tieulent R, Tikhonov A, Timmins AR, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Torres SR, Trifiró A, Tripathy S, Tripathy T, Trogolo S, Trombetta G, Tropp L, Trubnikov V, Trzaska WH, Trzcinski TP, Trzeciak BA, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Umaka EN, Uras A, Usai GL, Vala M, Valle N, Vallero S, van der Kolk N, van Doremalen LVR, van Leeuwen M, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vargas A, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vernet R, Vértesi R, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vrláková J, Wagner B, Weber M, Weber SG, Wegrzynek A, Wenzel SC, Wessels JP, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Willsher E, Windelband B, Winn M, Witt WE, Wright JR, Wu Y, Xu R, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yuan S, Yuncu A, Yurchenko V, Zaccolo V, Zaman A, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zhalov M, Zhang S, Zhang X, Zhang Z, Zherebchevskii V, Zhi Y, Zhou D, Zhou Y, Zhou Z, Zhu J, Zhu Y, Zichichi A, Zinovjev G, Zurlo N. Soft-Dielectron Excess in Proton-Proton Collisions at sqrt[s]=13 TeV. PHYSICAL REVIEW LETTERS 2021; 127:042302. [PMID: 34355943 DOI: 10.1103/physrevlett.127.042302] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 04/12/2021] [Accepted: 06/08/2021] [Indexed: 06/13/2023]
Abstract
A measurement of dielectron production in proton-proton (pp) collisions at sqrt[s]=13 TeV, recorded with the ALICE detector at the CERN LHC, is presented in this Letter. The data set was recorded with a reduced magnetic solenoid field. This enables the investigation of a kinematic domain at low dielectron (ee) invariant mass m_{ee} and pair transverse momentum p_{T,ee} that was previously inaccessible at the LHC. The cross section for dielectron production is studied as a function of m_{ee}, p_{T,ee}, and event multiplicity dN_{ch}/dη. The expected dielectron rate from hadron decays, called hadronic cocktail, utilizes a parametrization of the measured η/π^{0} ratio in pp and proton-nucleus collisions, assuming that this ratio shows no strong dependence on collision energy at low transverse momentum. Comparison of the measured dielectron yield to the hadronic cocktail at 0.15<m_{ee}<0.6 GeV/c^{2} and for p_{T,ee}<0.4 GeV/c indicates an enhancement of soft dielectrons, reminiscent of the "anomalous" soft-photon and soft-dilepton excess in hadron-hadron collisions reported by several experiments under different experimental conditions. The enhancement factor over the hadronic cocktail amounts to 1.61±0.13(stat)±0.17(syst,data)±0.34(syst,cocktail) in the ALICE acceptance. Acceptance-corrected excess spectra in m_{ee} and p_{T,ee} are extracted and compared with calculations of dielectron production from hadronic bremsstrahlung and thermal radiation within a hadronic many-body approach.
Collapse
|
57
|
Werth V, Merrill J, Furie R, Dörner T, Van Vollenhoven R, Lipsky P, Weiswasser M, Korish S, Schafer P, Stern M, Liu Z, Tang S, Delev N. OP0132 EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2181] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Iberdomide is a high-affinity cereblon ligand that promotes proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors involved in innate and adaptive immune cell development and homeostasis, and linked to the genetic risk for systemic lupus erythematosus (SLE). A phase 2, placebo-controlled study evaluated the efficacy and safety of iberdomide in patients (pts) with moderate to severe SLE.Objectives:To examine the effect of iberdomide on cutaneous manifestations in SLE pts.Methods:Adult autoantibody-positive SLE pts with a SLE Disease Activity Index 2000 (SLEDAI 2K) score ≥6 were randomized (2:2:1:2) to oral iberdomide (0.45, 0.3, 0.15 mg) or placebo once daily (QD) for 24 weeks while continuing standard background lupus medications. The Cutaneous Lupus Area and Severity Index Activity score (CLASI-A) was assessed every 4 weeks through week 24. As prespecified, exploratory analyses, change from baseline and the proportion of pts who achieved ≥50% reduction from baseline (CLASI-50) were evaluated for all pts, pts with baseline CLASI-A ≥8, and by cutaneous lupus subtypes (acute [ACLE], subacute [SCLE], chronic [CCLE]). CLASI-A outcomes were also evaluated post hoc for subgroups with high baseline expression of IKZF3 or the type 1 interferon (IFN) gene signatures in the blood.Results:Of 288 randomized pts, the mean and median (range) baseline CLASI-A scores were 6.9 and 5.0 (0-49), with 28% of pts having a score ≥8. 56% of pts had ACLE, 29% CCLE, and 16% SCLE. CLASI-50 responses were not significantly different comparing iberdomide to placebo in all pts and pts with baseline CLASI-A ≥8 at week 24, where high placebo response rates were observed (Table). Numerically greater mean improvement from baseline in CLASI-A scores in pts with baseline CLASI-A ≥8 was observed for iberdomide 0.45 mg vs placebo beginning at week 4, with continuous improvement through week 24. For pts with SCLE or CCLE, CLASI-50 response rates were significantly higher with iberdomide 0.45 mg vs placebo (P<0.04; Table). SCLE pts had significantly greater mean change and median percent improvement in CLASI-A from baseline with iberdomide 0.45 mg vs placebo at week 24 (P<0.03). Treatment differences in CLASI-A between iberdomide 0.45 mg and placebo were larger for SCLE and CCLE subgroups with high baseline IKZF3 or type 1 IFN gene signatures, with statistical significance achieved for SCLE pts but not CCLE pts (Figure).Table 1.CLASI-50 Response Rates by Subgroups at Week 240.15 mg QD0.3 mg QD0.45 mg QD(n=42)(n=82)(n=81)PlaceboSubgroup(n=83)0.15 mg QD vs Placebo0.3 mg QD vs Placebo0.45 mg QD vs Placebon/m (%)n/m (%)Str Diff in % (95% CI)P valuen/m (%)Str Diff in % (95% CI)P valuen/m (%)Str Diff in % (95% CI)P valueAll pts37/83 (44.6)19/42 (45.2)0.4 (-17.33, 18.55) P=0.96141/82 (50.0)5.3 (-9.93, 20.11) P=0.49945/81 (55.6)10.9 (-4.30, 25.51) P=0.163CLASI-A ≥810/20 (50.0)8/13 (61.5)15.9 (-17.42, 45.45) P=0.39913/24 (54.2)12.1 (-17.57, 39.97) P=0.45816/24 (66.7)15.1 (-15.51, 42.49) P=0.368ACLE23/50 (46.0)15/30 (50.0)4.8 (-17.22, 26.31) P=0.66220/43 (46.5)-3.3 (-22.95, 16.67) P=0.73817/38 (44.7)-3.0 (-23.20, 17.65) P=0.782SCLE9/17 (52.9)5/9 (55.6)2.6a (-33.04, 36.33) P=0.9663/9 (33.3)-6.6 (-38.98, 31.86) P>0.99911/12 (91.7)38.7a(4.54, 61.75) P=0.035CCLE5/18 (27.8)7/14 (50.0)22.2a (-10.51, 50.00) P=0.19810/23 (43.5)23.8 (-6.89, 48.88) P=0.12918/29 (62.1)34.1 (4.43, 56.16) P=0.029CI, confidence interval; Str Diff, stratified difference.aUnstratified difference.Conclusion:Iberdomide showed beneficial effects on skin manifestations in pts with SLE. Efficacy appears to be more pronounced in pts with SCLE and CCLE skin subtypes, and in pts with high IKZF3 or IFN gene expression signatures.Δ, treatment difference of adjusted means; CCLE, chronic cutaneous lupus erythematosus; CLASI-A, Cutaneous Lupus Erythematosus Disease Area and Severity Index-activity score; IFN, interferon; SCLE, subacute cutaneous lupus erythematosus.Acknowledgements:This study was sponsored by Bristol Myers Squibb. Professional medical writing assistance was provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Bristol Myers Squibb.Disclosure of Interests:Victoria Werth Consultant of: Bristol Myers Squibb, Grant/research support from: Bristol Myers Squibb, Joan Merrill Consultant of: UCB, GlaxoSmithKline, AbbVie, EMD Serono, Remegen, Celgene/Bristol Myers Squibb, AstraZeneca, Lilly, Immupharma, Amgen, Janssen, Resolve, Alpine, Aurinia, Astellas, Alexion, and Provention, Grant/research support from: GlaxoSmithKline and AstraZeneca, Richard Furie Consultant of: Bristol Myers Squibb, Grant/research support from: Bristol Myers Squibb, Thomas Dörner Consultant of: support for clinical studies and honoraria for scientific advice: AbbVie, Bristol Myers Squibb Company, Celgene, Eli Lilly, Janssen, Novartis, Roche, Employee of: Charite Universitätsmedizin, Berlin and DRFZ Berlin, Germany, Ronald van Vollenhoven Speakers bureau: UCB, AbbVie, Galapagos, Janssen, Pfizer, Paid instructor for: support for educational programs: Pfizer, Roche, Consultant of: AstraZeneca, Biogen, Biotest, Celgene, Gilead, Servier, UCB, AbbVie, Galapagos, Janssen, Pfizer, Grant/research support from: Bristol Myers Squibb, GlaxoSmithKline, Eli Lilly, UCB, Peter Lipsky Employee of: RILITE Foundation, Michael Weiswasser Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Shimon Korish Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Peter Schafer Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Mark Stern Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Zhaohui Liu Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Shaojun Tang Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Nikolay Delev Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb
Collapse
|
58
|
Acharya S, Adamová D, Adler A, Adolfsson J, Aggarwal MM, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Akbar Z, Akindinov A, Al-Turany M, Alam SN, Albuquerque DSD, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Anaam MN, Andrei C, Andreou D, Andronic A, Angeletti M, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arratia M, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bagnasco S, Bai X, Bailhache R, Bala R, Balbino A, Baldisseri A, Ball M, Balouza S, Banerjee D, Barbera R, Barioglio L, Barnaföldi GG, Barnby LS, Barret V, Bartalini P, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Bedda C, Behera NK, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berenyi D, Bertens RA, Berzano D, Besoiu MG, Betev L, Bhasin A, Bhat IR, Bhat MA, Bhatt H, Bhattacharjee B, Bianchi A, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Bilandzic A, Biro G, Biswas R, Biswas S, Blair JT, Blau D, Blume C, Boca G, Bock F, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruna E, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buncic P, Buthelezi Z, Butt JB, Bysiak SA, Caffarri D, Caliva A, Calvo Villar E, Camacho JMM, Camacho RS, Camerini P, Canedo FDM, Capon AA, Carnesecchi F, Caron R, Castillo Castellanos J, Castro AJ, Casula EAR, Catalano F, Ceballos Sanchez C, Chakraborty P, Chandra S, Chang W, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Chowdhury T, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cilladi LD, Cindolo F, Ciupek MR, Clai G, Cleymans J, Colamaria F, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Cormier TM, Corrales Morales Y, Cortese P, Cosentino MR, Costa F, Costanza S, Crochet P, Cuautle E, Cui P, Cunqueiro L, Dabrowski D, Dahms T, Dainese A, Damas FPA, Danisch MC, Danu A, Das D, Das I, Das P, Das P, Das S, Dash A, Dash S, De S, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, Deb S, Degenhardt HF, Deja KR, Deloff A, Delsanto S, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Dillenseger P, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Dobrin A, Dönigus B, Dordic O, Dubey AK, Dubla A, Dudi S, Dukhishyam M, Dupieux P, Ehlers RJ, Eikeland VN, Elia D, Erazmus B, Erhardt F, Erokhin A, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Festanti A, Feuillard VJG, Figiel J, Filchagin S, Finogeev D, Fionda FM, Fiorenza G, Flor F, Flores AN, Foertsch S, Foka P, Fokin S, Fragiacomo E, Frankenfeld U, Fuchs U, Furget C, Furs A, Fusco Girard M, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gauger EF, Gay Ducati MB, Germain M, Ghosh J, Ghosh P, Ghosh SK, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Gomez Ramirez A, Gonzalez V, González-Trueba LH, Gorbunov S, Görlich L, Goswami A, Gotovac S, Grabski V, Graczykowski LK, Graham KL, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Groettvik OS, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guernane R, Guittiere M, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Guzman IB, Haake R, Habib MK, Hadjidakis C, Hamagaki H, Hamar G, Hamid M, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hasenbichler JA, Hassan H, Hassan QU, Hatzifotiadou D, Hauer P, Havener LB, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herghelegiu A, Herman T, Hernandez EG, Herrera Corral G, Herrmann F, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hohlweger B, Honermann J, Horak D, Hornung A, Hornung S, Hosokawa R, Hristov P, Huang C, Hughes C, Huhn P, Humanic TJ, Hushnud H, Husova LA, Hussain N, Hussain SA, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Janson T, Jercic M, Jevons O, Jin M, Jonas F, Jones PG, Jung J, Jung M, Jusko A, Kalinak P, Kalweit A, Kaplin V, Kar S, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Keil M, Ketzer B, Khabanova Z, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim B, Kim D, Kim DJ, Kim EJ, Kim H, Kim J, Kim JS, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein C, Klein J, Klein S, Klein-Bösing C, Kleiner M, Kluge A, Knichel ML, Knospe AG, Kobdaj C, Köhler MK, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koska L, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Krüger M, Kryshen E, Krzewicki M, Kubera AM, Kučera V, Kuhn C, Kuijer PG, Kumar L, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lamanna M, Langoy R, Lapidus K, Lardeux A, Larionov P, Laudi E, Lavicka R, Lazareva T, Lea R, Leardini L, Lee J, Lee S, Lehner S, Lehrbach J, Lemmon RC, León Monzón I, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lindenstruth V, Lindner A, Lippmann C, Lisa MA, Liu A, Liu J, Liu S, Llope WJ, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmood SM, Mahmoud T, Maire A, Majka RD, Malaev M, Malik QW, Malinina L, Mal'Kevich D, Malzacher P, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Marchisone M, Mareš J, Margagliotti GV, Margotti A, Marín A, Markert C, Marquard M, Martin CD, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Masson E, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazzaschi F, Mazzilli M, Mazzoni MA, Mechler AF, Meddi F, Melikyan Y, Menchaca-Rocha A, Mengke C, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohammadi N, Mohanty AP, Mohanty B, Khan MM, Moravcova Z, Mordasini C, Moreira De Godoy DA, Moreno LAP, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myers CJ, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Naru MU, Nassirpour AF, Nattrass C, Nayak R, Nayak TK, Nazarenko S, Neagu A, Negrao De Oliveira RA, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Neumann LT, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Oppedisano C, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oyama K, Pachmayer Y, Pacik V, Padhan S, Pagano D, Paić G, Pan J, Panebianco S, Pareek P, Park J, Parkkila JE, Parmar S, Pathak SP, Paul B, Pazzini J, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Pistone D, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Poljak N, Pop A, Porteboeuf-Houssais S, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Putschke J, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Raha S, Rajput S, Rak J, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Raniwala R, Raniwala S, Räsänen SS, Rath R, Ratza V, Ravasenga I, Read KF, Redelbach AR, Redlich K, Rehman A, Reichelt P, Reidt F, Ren X, Renfordt R, Rescakova Z, Reygers K, Riabov A, Riabov V, Richert T, Richter M, Riedler P, Riegler W, Riggi F, Ristea C, Rode SP, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rohr D, Röhrich D, Rojas PF, Rokita PS, Ronchetti F, Rosano A, Rosas ED, Roslon K, Rossi A, Rotondi A, Roy A, Roy P, Rueda OV, Rui R, Rumyantsev B, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Saarimaki OAM, Sadek R, Sadhu S, Sadovsky S, Šafařík K, Saha SK, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu PK, Saini J, Sakai S, Sambyal S, Samsonov V, Sarkar D, Sarkar N, Sarma P, Sarti VM, Sas MHP, Scapparone E, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Serebryakov D, Sevcenco A, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma A, Sharma H, Sharma M, Sharma N, Sharma S, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silvermyr D, Simatovic G, Simonetti G, Singh B, Singh R, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Slupecki M, Smirnov N, Snellings RJM, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Steffanic PJ, Stenlund E, Stiefelmaier SF, Stocco D, Storetvedt MM, Stritto LD, Suaide AAP, Sugitate T, Suire C, Suleymanov M, Suljic M, Sultanov R, Šumbera M, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tarhini M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Thakur D, Thakur S, Thomas D, Thoresen F, Tieulent R, Tikhonov A, Timmins AR, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Torres SR, Trifiró A, Tripathy S, Tripathy T, Trogolo S, Trombetta G, Tropp L, Trubnikov V, Trzaska WH, Trzcinski TP, Trzeciak BA, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Umaka EN, Uras A, Usai GL, Vala M, Valle N, Vallero S, van der Kolk N, van Doremalen LVR, van Leeuwen M, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vargas A, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vernet R, Vértesi R, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vrláková J, Wagner B, Weber M, Weber SG, Wegrzynek A, Wenzel SC, Wessels JP, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Willsher E, Windelband B, Winn M, Witt WE, Wright JR, Wu Y, Xu R, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yuan S, Yuncu A, Yurchenko V, Zaccolo V, Zaman A, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zhalov M, Zhang S, Zhang X, Zhang Z, Zherebchevskii V, Zhi Y, Zhou D, Zhou Y, Zhou Z, Zhu J, Zhu Y, Zichichi A, Zinovjev G, Zurlo N. Elliptic Flow of Electrons from Beauty-Hadron Decays in Pb-Pb Collisions at sqrt[s_{NN}]=5.02 TeV. PHYSICAL REVIEW LETTERS 2021; 126:162001. [PMID: 33961482 DOI: 10.1103/physrevlett.126.162001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 01/27/2021] [Accepted: 03/09/2021] [Indexed: 06/12/2023]
Abstract
The elliptic flow of electrons from beauty hadron decays at midrapidity (|y|<0.8) is measured in Pb-Pb collisions at sqrt[s_{NN}]=5.02 TeV with the ALICE detector at the LHC. The azimuthal distribution of the particles produced in the collisions can be parametrized with a Fourier expansion, in which the second harmonic coefficient represents the elliptic flow, v_{2}. The v_{2} coefficient of electrons from beauty hadron decays is measured for the first time in the transverse momentum (p_{T}) range 1.3-6 GeV/c in the centrality class 30%-50%. The measurement of electrons from beauty-hadron decays exploits their larger mean proper decay length cτ≈500 μm compared to that of charm hadrons and most of the other background sources. The v_{2} of electrons from beauty hadron decays at midrapidity is found to be positive with a significance of 3.75 σ. The results provide insights into the degree of thermalization of beauty quarks in the medium. A model assuming full thermalization of beauty quarks is strongly disfavored by the measurement at high p_{T}, but is in agreement with the results at low p_{T}. Transport models including substantial interactions of beauty quarks with an expanding strongly interacting medium describe the measurement within uncertainties.
Collapse
|
59
|
Abstract
OBJECTIVES To evaluate the recurrence risk of stillbirth. DESIGN Retrospective cohort study. SETTING AND POPULATION All births 1992-2017, Alberta, Canada. METHODS Retrospective cohort study. MAIN OUTCOME MEASURES Stillbirth was defined as the death in utero of a fetus with gestational age ≥20 weeks or weighing ≥500 g. Stillbirths were further subdivided into those occurring before labour and those in labour. RESULTS We identified 744 897 births from 308 478 women. Of these, 3698 women experienced a stillbirth and, of these, 97.7%, experienced only one. For women with a small-for-gestational- age stillbirth in the first birth, their risk of a subsequent antepartum stillbirth was increased substantially: 4.09%, relative risk (RR) 10.39, 95% CI 5.81-18.59. For women with a first birth appropriate-for-gestational-age stillbirth with no risk factors such as pregnancy induced hypertension, the risk with pre-existing diabetes mellitus or hypertension was also increased but to a much lesser degree (RR 2.46, 95% CI 1.23-4.91). For women who had experienced a first birth intrapartum stillbirth, the risk of another intrapartum stillbirth was very high (3.59%, RR 36.50, 95% CI 20.17-66.05). Most of these births also occurred prior to 24 weeks' gestation: 83% (10/12). CONCLUSIONS The risk of recurrent antepartum stillbirth is low. The increase in risk in instances where the antepartum stillbirth was not growth-restricted is not clinically meaningful. Given the very low risk in any given gestational week, fetal surveillance is unlikely to be effective and may lead to unnecessary interventions. Intrapartum stillbirth has a very high recurrence risk but may not be preventable. TWEETABLE ABSTRACT Stillbirth recurrence is rare.
Collapse
|
60
|
Li J, Zeng T, Tang S, Zhong M, Huang Q, Li X, He X. Medical ozone induces proliferation and migration inhibition through ROS accumulation and PI3K/AKT/NF-κB suppression in human liver cancer cells in vitro. Clin Transl Oncol 2021; 23:1847-1856. [PMID: 33821368 DOI: 10.1007/s12094-021-02594-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 03/09/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND Hepatocellular carcinoma is one of the most common malignancies and leading cancer-associated deaths worldwide. Ozone has been proposed as a promising therapeutic agent in the treatment of various disorders. PURPOSE The purpose of this paper is to assess the potential anticancer effects of the ozone on liver cancer cells. METHOD The liver cancer cell line of bel7402 and SMMC7721 was used in this study. Proliferation was evaluated using the CCK-8 and the colony formation assay. Wond healing assay and transwell assay without Matrigel were used to evaluate their migration ability. Flow cytometry was used for cell cycle analysis and reactive oxygen species (ROS) determination. Glutathione detection kit was used for measurement of glutathione level. Protein expression was estimated by western blot analysis. RESULTS Ozone treatment inhibited liver cancer cell proliferation, colony formation. Ozone induced G2/M phase cell cycle arrest, which could be elucidated by the change of protein levels of p53, p21, Cyclin D1, cyclin B1, cdc2, and CDK4. We also found that ozone treatment inhibited migration ability by inhibiting EMT-relating protein. Ozone also induced ROS accumulation and decreased glutathione level decreased, which contributed to the inactivation of the PI3K/AKT/NF-κB pathway. Finally, we found that pre-treatment of liver cancer cells with N-acetylcysteine resisted ozone-induced effects. CONCLUSIONS Ozone restrains the proliferation and migration potential and EMT process of liver cancer cells via ROS accumulation and PI3K/AKT/NF-κB suppression.
Collapse
|
61
|
Lidington E, Darlington AS, Vlooswijk C, Beardsworth S, McCaffrey S, Tang S, Stallard K, Younger E, Edwards P, Ali AI, Nandhabalan M, Din A, Starling N, Larkin J, Stanway S, Nobbenhuis M, Banerjee S, Szucs Z, Gonzalez M, Sirohi B, Husson O, van der Graaf WTA. Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25-39 Years Old in the UK National Health Service. Clin Oncol (R Coll Radiol) 2021; 33:494-506. [PMID: 33722412 DOI: 10.1016/j.clon.2021.02.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 02/04/2021] [Accepted: 02/17/2021] [Indexed: 11/17/2022]
Abstract
AIMS Adolescents and young adults aged 15-39 years with cancer face unique medical, practical and psychosocial issues. In the UK, principal treatment centres and programmes have been designed to care for teenage and young adult patients aged 13-24 years in an age-appropriate manner. However, for young adults (YAs) aged 25-39 years with cancer, little access to age-specific support is available. The aim of this study was to examine this possible gap by qualitatively exploring YA care experiences, involving patients as research partners in the analysis to ensure robust results. MATERIALS AND METHODS We conducted a phenomenological qualitative study with YAs diagnosed with any cancer type between ages 25 and 39 years old in the last 5 years. Participants took part in interviews or focus groups and data were analysed using inductive thematic analysis. Results were shaped in an iterative process with the initial coders and four YA patients who did not participate in the study to improve the rigor of the results. RESULTS Sixty-five YAs with a range of tumour types participated. We identified seven themes and 13 subthemes. YAs found navigating the healthcare system difficult and commonly experienced prolonged diagnostic pathways. Participants felt under-informed about clinical details and the long-term implications of side-effects on daily life. YAs found online resources overwhelming but also a source of information and treatment support. Some patients regretted not discussing fertility before cancer treatment or felt uninformed or rushed when making fertility preservation decisions. A lack of age-tailored content or age-specific groups deterred YAs from accessing psychological support and rehabilitation services. CONCLUSIONS YAs with cancer may miss some benefits provided to teenagers and young adults in age-tailored cancer services. Improving services for YAs in adult settings should focus on provision of age-specific information and access to existing relevant support.
Collapse
|
62
|
Ding Y, Tang S, Li S, Yang C, Liu T, Ying S, Zhu D, Sun C, Chen W, Shi Y, Fang H, Qiao J. Risk of macrophage activation syndrome in patients with adult-onset Still's disease with skin involvement: A retrospective cohort study. J Am Acad Dermatol 2021; 85:1503-1509. [PMID: 33556412 DOI: 10.1016/j.jaad.2021.02.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 01/22/2021] [Accepted: 02/01/2021] [Indexed: 11/15/2022]
Abstract
BACKGROUND Small case series and case reports indicated that atypical persistent pruritic eruptions (PPEs), another type of skin lesions seen in adult-onset Still's disease (AOSD), imply a worse prognosis than typical evanescent rashes. OBJECTIVE To investigate clinical characteristics and macrophage activation syndrome (MAS) occurrence in AOSD with PPEs. METHODS A retrospective cohort study analyzed 150 patients with AOSD with rashes at the First Affiliated Hospital of Zhejiang University from January 2013 to December 2019. RESULTS Patients with AOSD with PPEs had higher lactate dehydrogenase (492.00 U/L vs 382.00 U/L; P < .001) and ferritin (6944.10 ng/ml vs 4286.60 ng/ml; P = .033), and lower fibrinogen (5.05 g/L vs 5.77 g/L; P = .014) than those with evanescent rashes. Patients with AOSD with PPEs had a higher incidence (17.4% vs 3.1%, P = .006) and cumulative event rate for MAS (P = .008) and tended to receive high-dose glucocorticoid (36% vs 20.3%; P = .036). Multivariate analysis indicated that PPEs (hazard ratio [HR], 5.519; 95% confidence interval [CI], 1.138-26.767; P = .034), aspartate aminotransferase of greater than 120 U/L (HR, 8.084; 95% CI, 1.728-37.826; P = .008), and splenomegaly (HR, 21.152; 95% CI, 2.263-197.711; P = .007) were independent risk factors for MAS. LIMITATIONS Single-center, retrospective nature, small sample size. CONCLUSION PPEs indicated increased severity and MAS occurrence versus evanescent rashes. PPEs, aspartate aminotransferase of greater than 120 U/L, and splenomegaly were risk factors for MAS in AOSD with skin involvement.
Collapse
|
63
|
Tang S, Salazar-Puerta A, Richards J, Khan S, Hoyland JA, Gallego-Perez D, Walter B, Higuita-Castro N, Purmessur D. Non-viral reprogramming of human nucleus pulposus cells with FOXF1 via extracellular vesicle delivery: an in vitro and in vivo study. Eur Cell Mater 2021; 41:90-107. [PMID: 33465243 PMCID: PMC8514169 DOI: 10.22203/ecm.v041a07] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Intervertebral disc (IVD) degeneration is characterized by decreased cellularity and proteoglycan synthesis and increased inflammation, catabolism, and neural/vascular ingrowth. Regenerative methods for IVD degeneration are largely cell-therapy-based or involve viral vectors, which are associated with mutagenesis and undesired immune responses. The present study used bulk electroporation and engineered extracellular vesicles (EVs) to deliver forkhead-box F1 (FOXF1) mRNA to degenerate human nucleus pulposus (NP) cells as a minimally invasive therapeutic strategy for IVD regeneration. Bulk electroporation was used to investigate FOXF1 effects on human NP cells during a 4-week culture in 3D agarose constructs. Engineered EV delivery of FOXF1 into human IVD cells in monolayer was determined, with subsequent in vivo validation in a pilot mouse IVD puncture model. FOXF1 transfection significantly altered gene expression by upregulating healthy NP markers [FOXF1, keratin 19 (KRT19)], decreasing inflammatory cytokines [interleukin (IL)-1β, -6], catabolic enzymes [metalloproteinase 13 (MMP13)] and nerve growth factor (NGF), with significant increases in glycosaminoglycan accumulation in human NP cells. Engineered EVs loaded with FOXF1 demonstrated successful encapsulation of FOXF1 cargo and effective uptake by human NP cells cultured in monolayer. Injection of FOXF1-loaded EVs into the mouse IVD in vivo resulted in a significant upregulation of FOXF1 and Brachyury, compared to controls at 7 d post-injection, with no evidence of cytotoxicity. This is the first study to demonstrate non-viral delivery of FOXF1 and reprogramming of human NP cells in vitro and mouse IVD cells in vivo. This strategy represents a non-addictive approach for treating IVD degeneration and associated back pain.
Collapse
|
64
|
Tang S, Li S, Zheng S, Ding Y, Zhu D, Sun C, Hu Y, Qiao J, Fang H. Understanding of cytokines and targeted therapy in macrophage activation syndrome. Semin Arthritis Rheum 2020; 51:198-210. [PMID: 33385860 DOI: 10.1016/j.semarthrit.2020.12.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 12/01/2020] [Accepted: 12/21/2020] [Indexed: 12/29/2022]
Abstract
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of systemic autoinflammatory/autoimmune diseases, generally systemic juvenile idiopathic arthritis and adult-onset Still's disease. It is characterized by an excessive proliferation of macrophages and T lymphocytes. Recent research revealed that cytokine storm with elevated pro-inflammatory cytokines, including IFN-γ, IL-18, and IL-6, may be central to the pathogenesis of MAS. Though the mainstream of MAS treatment remains corticosteroids and cyclosporine, targeted therapies with anti-cytokine biologics are reported to be promising for controlling systemic inflammation in MAS.
Collapse
|
65
|
Deng FC, Wang C, Gu W, Chen YY, Han JJ, Du HM, Peng H, Tang S. [Research advances in the adverse effects of azo dyes]. ZHONGHUA YU FANG YI XUE ZA ZHI [CHINESE JOURNAL OF PREVENTIVE MEDICINE] 2020; 54:1478-1483. [PMID: 33333672 DOI: 10.3760/cma.j.cn112150-20200114-00020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
China is the world's largest producer and user of dyes. The mass production and widespread use of disperse azo dyes led to environmental pollutions and potential human health risks. Azo dyes in environmental media (i.e., water, soil, air, and dust), food and clothing can enter the human body through multiple exposure routes, and some of them can be metabolized to produce more toxic metabolites, which can trigger toxic effects such as allergic reactions, tumor formation, and endocrine disruptions. This study systematically reviewed the production and use of azo dyes, environmental concentrations, human exposures, toxic effects and their underlying mechanisms, and regulations and standards. Meanwhile, the research trends of azo dyes were also discussed.
Collapse
|
66
|
Yang C, Tang S, Zhu D, Ding Y, Qiao J. Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification. Front Med (Lausanne) 2020; 7:587773. [PMID: 33330547 PMCID: PMC7710911 DOI: 10.3389/fmed.2020.587773] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Accepted: 10/08/2020] [Indexed: 12/13/2022] Open
Abstract
Systemic sclerosis (SSc) is an autoimmune disease characterized by abnormalities in microcirculation, extracellular matrix accumulation, and immune activation. Autoantibodies are markers of immune abnormalities and provide diagnostic and predictive value in SSc. Anti-topoisomerase antibodies (ATAs), anticentromere antibodies (ACAs), and anti-RNA polymerase antibodies (ARAs) are the three classical specific antibodies with the highest availability and stability. In this review, we provide an overview of the recent progress in SSc research with respect to ATAs, ACAs, and ARAs, focusing on their application in distinguishing clinical phenotypes, such as malignancy and organ involvement, identifying genetic background in human leukocyte antigen (HLA) or non-HLA alleles, and their potential roles in disease pathogenesis based on the effects of antigen-antibody binding. We finally summarized the novel analysis using ATAs, ACAs, and ARAs on more detailed disease clusters. Considering these advantages, this review emphasizes that classical SSc-specific autoantibodies are still practical and have the potential for patient and risk stratification with applications in precise medicine for SSc.
Collapse
|
67
|
Liu T, Li S, Ying S, Tang S, Ding Y, Li Y, Qiao J, Fang H. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front Immunol 2020; 11:594735. [PMID: 33281823 PMCID: PMC7705238 DOI: 10.3389/fimmu.2020.594735] [Citation(s) in RCA: 113] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 10/20/2020] [Indexed: 12/13/2022] Open
Abstract
Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is associated with the pathogenesis of inflammatory diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Interleukin-23 (IL-23) plays a pivotal role in stimulating the production of IL-17 by activating the Th17 cells. The IL-23/IL-17 axis is an important pathway for targeted therapy for inflammatory diseases. Emerging evidence from clinical trials has shown that monoclonal antibodies against IL-23, IL-17, and tumor necrosis factor are effective in the treatment of patients with psoriasis, atopic dermatitis, hidradenitis suppurativa, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Here, we summarize the latest knowledge about the biology, signaling, and pathophysiological functions of the IL-23/IL-17 axis in inflammatory skin diseases. The currently available biologics targeting the axis is also discussed.
Collapse
|
68
|
Trivedi S, Tang S, Otton J, Delaney G, Holloway L, Liney G, Koh E, Thomas L. Regional cardiac dysfunction determined by radiation dose in patients with breast cancer. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Subclinical left ventricular (LV) dysfunction by 2D global longitudinal strain (GLS) immediately following radiotherapy (RT) and persisting at 12 months has been described in breast cancer (BC) patients. We hypothesised that persistent LV dysfunction may be regional and correlate with segmental RT.
Methods
Transthoracic echocardiograms were performed at baseline, 6 weeks and 12 months post-RT on 61 chemotherapy-naïve women with left sided BC.
Results
Anterior and anteroseptal regions received the highest radiation dose, and posterior and inferior segments the lowest radiation dose (Figure 1). Within each region, there was a progressive increase in the radiation dose received from base to apex. At 6 weeks, the greatest reduction in strain was observed in the anterior and anteroseptal regions, with the most significant reduction in strain in the apical segments. At 12 months, despite improvement in strain, the percentage reduction in strain was similar. There was a significant interaction between both region and segment, on the percentage change in strain at 6 weeks (p<0.001) and at 12 months (p=0.007). Pairwise comparisons of apical to basal percentage change in strain demonstrated the most significant reductions in the anterior region at 6 weeks and 12 months (Table 1).
Conclusions
RT causes segmental myocardial dysfunction, with areas receiving the highest RT demonstrating the largest impairment in strain, with these changes persisting at 12 months. Long term correlation with adverse events is required.
Figure 1. Radiation dose by region and segment
Funding Acknowledgement
Type of funding source: None
Collapse
|
69
|
Li Z, Satchithanandha A, Hopkins A, Otton J, Descallar J, Adams D, Tang S, Field M, Batumalai V, Holloway L, Delaney G, Koh E. PH-0595: Cardiovascular sequelae after adjuvant therapy in a 10-year cohort of breast cancer patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00617-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
70
|
Li L, Tang S, Yin J, Pang J, Bao H, Ge H, Liu Y, Wang J, Dong L, Mu D, Yuan S, Wu X, Wang X, Shao Y, Yu J, Yuan S. Molecular Biomarkers for Chemoradiotherapy Response in Unresectable Limited Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
71
|
Liang X, Huang L, Ou Y, He Y, Tang S. Association between MAFB rs17820943 and rs6072081 polymorphism and risk of nonsyndromic cleft lip with or without cleft palate: a meta-analysis. Br J Oral Maxillofac Surg 2020; 58:1065-1072. [PMID: 32646788 DOI: 10.1016/j.bjoms.2020.05.034] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 05/20/2020] [Indexed: 02/05/2023]
Abstract
While there have been previous studies examining the relation between the rs17820943 and rs6072081 polymorphisms in the v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) gene and rates of nonsyndromic cleft lip with or without cleft palate (NSCL/P), at present the results of these studies have been inconsistent. This meta-analysis therefore aimed to conduct a more robust assessment of the association between the MAFB rs17820943 and rs6072081 polymorphisms and NSCL/P risk. The Embase, Web of Science, PubMed, the China National Knowledge Internet (CNKI), and Wanfang databases were systematically searched to identify relevant studies. In total, five studies incorporating 2769 patients and 2885 controls were identified assessing the rs17820943 polymorphism and three studies incorporating 1242 patients and 1310 controls assessing the rs6072081 polymorphism were identified. This analysis revealed the MAFB rs17820943 and rs6072081 polymorphisms to be linked to a significantly reduced NSCL/P risk (rs17820943: C vs T: OR=0.76, 95% CI=0.70-0.82; CC vs CT: OR=0.75, 95% CI=0.67-0.85; CC vs TT: OR=0.58, 95% CI=0.49-0.67; CC+CT vs TT: OR=0.67, 95% CI=0.59-0.77; CT+TT vs CC: OR=1.43, 95% CI=1.28-1.60; rs6072081: A vs G: OR=0.77, 95%CI=0.68-0.86; AA vs AG: OR=0.76, 95%CI=0.64-0.90; AA vs GG: OR=0.58, 95%CI=0.45-0.74; AA+AG vs GG: OR=0.68, 95%CI=0.54-0.84; AG+GG vs AA: OR=1.40, 95% CI=1.19-1.65). The results of the present meta-analysis indicate that in an East Asian population, for both rs17820943 and rs6072081 were associated with NSCL/P.
Collapse
|
72
|
Acharya S, Adamová D, Adler A, Adolfsson J, Aggarwal MM, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Akbar Z, Akindinov A, Al-Turany M, Alam SN, Albuquerque DSD, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Anaam MN, Andrei C, Andreou D, Andronic A, Angeletti M, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arratia M, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bagnasco S, Bai X, Bailhache R, Bala R, Balbino A, Baldisseri A, Ball M, Balouza S, Banerjee D, Barbera R, Barioglio L, Barnaföldi GG, Barnby LS, Barret V, Bartalini P, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Bedda C, Behera NK, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berenyi D, Bertens RA, Berzano D, Besoiu MG, Betev L, Bhasin A, Bhat IR, Bhat MA, Bhatt H, Bhattacharjee B, Bianchi A, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Bilandzic A, Biro G, Biswas R, Biswas S, Blair JT, Blau D, Blume C, Boca G, Bock F, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruna E, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buncic P, Buthelezi Z, Butt JB, Bysiak SA, Caffarri D, Caliva A, Calvo Villar E, Camacho JMM, Camacho RS, Camerini P, Canedo FDM, Capon AA, Carnesecchi F, Caron R, Castillo Castellanos J, Castro AJ, Casula EAR, Catalano F, Ceballos Sanchez C, Chakraborty P, Chandra S, Chang W, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Chowdhury T, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cilladi LD, Cindolo F, Ciupek MR, Clai G, Cleymans J, Colamaria F, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Cormier TM, Corrales Morales Y, Cortese P, Cosentino MR, Costa F, Costanza S, Crochet P, Cuautle E, Cui P, Cunqueiro L, Dabrowski D, Dahms T, Dainese A, Damas FPA, Danisch MC, Danu A, Das D, Das I, Das P, Das P, Das S, Dash A, Dash S, De S, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, Deb S, Degenhardt HF, Deja KR, Deloff A, Delsanto S, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Dillenseger P, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Dobrin A, Dönigus B, Dordic O, Dubey AK, Dubla A, Dudi S, Dukhishyam M, Dupieux P, Ehlers RJ, Eikeland VN, Elia D, Erazmus B, Erhardt F, Erokhin A, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Festanti A, Feuillard VJG, Figiel J, Filchagin S, Finogeev D, Fionda FM, Fiorenza G, Flor F, Flores AN, Foertsch S, Foka P, Fokin S, Fragiacomo E, Frankenfeld U, Fuchs U, Furget C, Furs A, Fusco Girard M, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gauger EF, Gay Ducati MB, Germain M, Ghosh J, Ghosh P, Ghosh SK, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Gomez Ramirez A, Gonzalez V, González-Trueba LH, Gorbunov S, Görlich L, Goswami A, Gotovac S, Grabski V, Graczykowski LK, Graham KL, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Groettvik OS, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guernane R, Guittiere M, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Guzman IB, Haake R, Habib MK, Hadjidakis C, Hamagaki H, Hamar G, Hamid M, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hasenbichler JA, Hassan H, Hassan QU, Hatzifotiadou D, Hauer P, Havener LB, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herghelegiu A, Herman T, Hernandez EG, Herrera Corral G, Herrmann F, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hohlweger B, Honermann J, Horak D, Hornung A, Hornung S, Hosokawa R, Hristov P, Huang C, Hughes C, Huhn P, Humanic TJ, Hushnud H, Husova LA, Hussain N, Hussain SA, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Janson T, Jercic M, Jevons O, Jin M, Jonas F, Jones PG, Jung J, Jung M, Jusko A, Kalinak P, Kalweit A, Kaplin V, Kar S, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Keil M, Ketzer B, Khabanova Z, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim B, Kim D, Kim DJ, Kim EJ, Kim H, Kim J, Kim JS, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein C, Klein J, Klein S, Klein-Bösing C, Kleiner M, Kluge A, Knichel ML, Knospe AG, Kobdaj C, Köhler MK, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koska L, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Krüger M, Kryshen E, Krzewicki M, Kubera AM, Kučera V, Kuhn C, Kuijer PG, Kumar L, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lamanna M, Langoy R, Lapidus K, Lardeux A, Larionov P, Laudi E, Lavicka R, Lazareva T, Lea R, Leardini L, Lee J, Lee S, Lehner S, Lehrbach J, Lemmon RC, León Monzón I, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lindenstruth V, Lindner A, Lippmann C, Lisa MA, Liu A, Liu J, Liu S, Llope WJ, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmood SM, Mahmoud T, Maire A, Majka RD, Malaev M, Malik QW, Malinina L, Mal'Kevich D, Malzacher P, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Marchisone M, Mareš J, Margagliotti GV, Margotti A, Marín A, Markert C, Marquard M, Martin CD, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Masson E, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazzaschi F, Mazzilli M, Mazzoni MA, Mechler AF, Meddi F, Melikyan Y, Menchaca-Rocha A, Mengke C, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohammadi N, Mohanty AP, Mohanty B, Mohisin Khan M, Moravcova Z, Mordasini C, Moreira De Godoy DA, Moreno LAP, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myers CJ, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Naru MU, Nassirpour AF, Nattrass C, Nayak R, Nayak TK, Nazarenko S, Neagu A, Negrao De Oliveira RA, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Neumann LT, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Oppedisano C, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oyama K, Pachmayer Y, Pacik V, Padhan S, Pagano D, Paić G, Pan J, Panebianco S, Pareek P, Park J, Parkkila JE, Parmar S, Pathak SP, Paul B, Pazzini J, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Pistone D, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Poljak N, Pop A, Porteboeuf-Houssais S, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Putschke J, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Raha S, Rajput S, Rak J, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Raniwala R, Raniwala S, Räsänen SS, Rath R, Ratza V, Ravasenga I, Read KF, Redelbach AR, Redlich K, Rehman A, Reichelt P, Reidt F, Ren X, Renfordt R, Rescakova Z, Reygers K, Riabov A, Riabov V, Richert T, Richter M, Riedler P, Riegler W, Riggi F, Ristea C, Rode SP, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rohr D, Röhrich D, Rojas PF, Rokita PS, Ronchetti F, Rosano A, Rosas ED, Roslon K, Rossi A, Rotondi A, Roy A, Roy P, Rueda OV, Rui R, Rumyantsev B, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Saarimaki OAM, Sadek R, Sadhu S, Sadovsky S, Šafařík K, Saha SK, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu PK, Saini J, Sakai S, Sambyal S, Samsonov V, Sarkar D, Sarkar N, Sarma P, Sarti VM, Sas MHP, Scapparone E, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Serebryakov D, Sevcenco A, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma A, Sharma H, Sharma M, Sharma N, Sharma S, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silvermyr D, Simatovic G, Simonetti G, Singh B, Singh R, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Slupecki M, Smirnov N, Snellings RJM, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Steffanic PJ, Stenlund E, Stiefelmaier SF, Stocco D, Storetvedt MM, Stritto LD, Suaide AAP, Sugitate T, Suire C, Suleymanov M, Suljic M, Sultanov R, Šumbera M, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tarhini M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Thakur D, Thakur S, Thomas D, Thoresen F, Tieulent R, Tikhonov A, Timmins AR, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Torres SR, Trifiró A, Tripathy S, Tripathy T, Trogolo S, Trombetta G, Tropp L, Trubnikov V, Trzaska WH, Trzcinski TP, Trzeciak BA, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Umaka EN, Uras A, Usai GL, Vala M, Valle N, Vallero S, van der Kolk N, van Doremalen LVR, van Leeuwen M, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vargas A, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vernet R, Vértesi R, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vrláková J, Wagner B, Weber M, Weber SG, Wegrzynek A, Wenzel SC, Wessels JP, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Willsher E, Windelband B, Winn M, Witt WE, Wright JR, Wu Y, Xu R, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yuan S, Yuncu A, Yurchenko V, Zaccolo V, Zaman A, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zhalov M, Zhang S, Zhang X, Zhang Z, Zherebchevskii V, Zhi Y, Zhou D, Zhou Y, Zhou Z, Zhu J, Zhu Y, Zichichi A, Zinovjev G, Zurlo N. Measurement of the Low-Energy Antideuteron Inelastic Cross Section. PHYSICAL REVIEW LETTERS 2020; 125:162001. [PMID: 33124836 DOI: 10.1103/physrevlett.125.162001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 08/10/2020] [Accepted: 09/09/2020] [Indexed: 06/11/2023]
Abstract
In this Letter, we report the first measurement of the inelastic cross section for antideuteron-nucleus interactions at low particle momenta, covering a range of 0.3≤p<4 GeV/c. The measurement is carried out using p-Pb collisions at a center-of-mass energy per nucleon-nucleon pair of sqrt[s_{NN}]=5.02 TeV, recorded with the ALICE detector at the CERN LHC and utilizing the detector material as an absorber for antideuterons and antiprotons. The extracted raw primary antiparticle-to-particle ratios are compared to the results from detailed ALICE simulations based on the geant4 toolkit for the propagation of (anti)particles through the detector material. The analysis of the raw primary (anti)proton spectra serves as a benchmark for this study, since their hadronic interaction cross sections are well constrained experimentally. The first measurement of the inelastic cross section for antideuteron-nucleus interactions averaged over the ALICE detector material with atomic mass numbers ⟨A⟩=17.4 and 31.8 is obtained. The measured inelastic cross section points to a possible excess with respect to the Glauber model parametrization used in geant4 in the lowest momentum interval of 0.3≤p<0.47 GeV/c up to a factor 2.1. This result is relevant for the understanding of antimatter propagation and the contributions to antinuclei production from cosmic ray interactions within the interstellar medium. In addition, the momentum range covered by this measurement is of particular importance to evaluate signal predictions for indirect dark-matter searches.
Collapse
|
73
|
Xie X, Shen Y, Tang S, Cheng X, Lv W, Wan X, Chen Z. Intraperitoneal chemotherapy as first-line treatment of newly diagnosed advanced epithelial ovarian cancer: Two centers' data in China. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
74
|
Xie X, Jin L, Tang S, Shen Y, Cheng X, Lv W, Wan X, Chen Z. What influences the long-term survival of advanced high-grade serous ovarian cancer? Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
75
|
Xie X, Tang S, Jin L, Shen Y, Cheng X, Lv W, Wan X, Chen Z. Secondary cytoreduction in relapsed serous ovarian cancer: Who really benefits? Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|